Ustekinumab Pens/Syringes or Biosimilar   2

Background
The Department of Veterans Affairs (VA) is seeking to establish a supply source for Ustekinumab pens/syringes or biosimilars through its Pharmaceutical Prime Vendor (PPV) Programs. The goal is to ensure availability and consistency of these pharmaceutical products for nationwide usage while obtaining volume-based, committed-use pricing. The contract will support the VA and Department of Defense (DoD) in acquiring their pharmaceutical requirements.

Work Details
The solicitation includes the following items:

1. **Ustekinumab 5MG/ML Injection, Solution, 26ML**
- Quantity: 2,917 syringes/vials for each year (Base Year and Option Years 1-4)
- NDC # and BLA# to be provided by the offeror.

2. **Ustekinumab 45MG/0.5ML Injection, 0.5ML**
- Quantity: 9,608 syringes/vials for each year (Base Year and Option Years 1-4)
- NDC # and BLA# to be provided by the offeror.

3. **Ustekinumab 90MG/ML Injection, Syringe, 1ML**
- Quantity: 45,763 syringes/vials for each year (Base Year and Option Years 1-4)
- NDC # and BLA# to be provided by the offeror.

Offerors must submit prices that include a Cost Recovery Fee of 0.5% and provide an 11-digit NDC number unique to their company for each drug offered. If both syringe and vial versions are available commercially, both must be offered at the same price.

Period of Performance
The contract will have an implementation period followed by an ordering period that includes a base year and four option years.

Place of Performance
Products will be delivered to various facilities under the VA PPV Program, including all Department of Veterans Affairs facilities, DoD facilities, Indian Health Service facilities, Bureau of Prisons facilities, and State Veterans Homes.